[{"address1": "275 Shoreline Drive", "address2": "Suite 500", "city": "Redwood City", "state": "CA", "zip": "94065", "country": "United States", "phone": "650 206 4507", "website": "https://www.rezolutebio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company's lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.", "fullTimeEmployees": 59, "companyOfficers": [{"maxAge": 1, "name": "Mr. Nevan Charles Elam J.D.", "age": 56, "title": "Founder, CEO, Principal Financial Officer & Acting Chairman of the Board", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 915668, "exercisedValue": 0, "unexercisedValue": 739888}, {"maxAge": 1, "name": "Mr. Daron G. Evans M.B.A., M.S.", "age": 49, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 183040, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Brian Kenneth Roberts M.D.", "age": 48, "title": "Chief Medical Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 712035, "exercisedValue": 0, "unexercisedValue": 216720}, {"maxAge": 1, "name": "Dr. Davelyn Eaves Hood M.B.A., M.D.", "title": "Director and Head of Scientific & Patient Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael R. Deperro", "title": "Senior VP & Head of Corporate Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Covarrubias", "title": "Senior VP & Head of Program & Portfolio Management", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chris  Milks", "title": "VP & Head of Finance", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raj  Agrawal M.D.", "title": "VP & Head of Ophthalmological Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Robyn  Sweinhart", "title": "VP & Head of Quality", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erin  O'Boyle", "title": "Senior VP & Head of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 4.76, "open": 4.82, "dayLow": 4.71, "dayHigh": 4.93, "regularMarketPreviousClose": 4.76, "regularMarketOpen": 4.82, "regularMarketDayLow": 4.71, "regularMarketDayHigh": 4.93, "beta": 1.188, "forwardPE": -4.46789, "volume": 242411, "regularMarketVolume": 242411, "averageVolume": 402472, "averageVolume10days": 384890, "averageDailyVolume10Day": 384890, "bid": 4.83, "ask": 4.9, "bidSize": 200, "askSize": 100, "marketCap": 282182880, "fiftyTwoWeekLow": 0.92, "fiftyTwoWeekHigh": 6.186, "fiftyDayAverage": 5.0088, "twoHundredDayAverage": 4.414925, "currency": "USD", "enterpriseValue": 192069056, "floatShares": 42030080, "sharesOutstanding": 57943100, "sharesShort": 1148577, "sharesShortPriorMonth": 1046477, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.020499999, "heldPercentInsiders": 0.13743, "heldPercentInstitutions": 0.64241, "shortRatio": 3.16, "shortPercentOfFloat": 0.028399998, "impliedSharesOutstanding": 57943100, "bookValue": 2.273, "priceToBook": 2.1425428, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -68459000, "trailingEps": -1.27, "forwardEps": -1.3, "lastSplitFactor": "1:50", "lastSplitDate": 1602547200, "enterpriseToEbitda": -2.729, "52WeekChange": 3.9693875, "SandP52WeekChange": 0.23631513, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RZLT", "underlyingSymbol": "RZLT", "shortName": "Rezolute, Inc.", "longName": "Rezolute, Inc.", "firstTradeDateEpochUtc": 1358173800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f60a9d03-38b9-338b-8f55-04bb3c9be16c", "messageBoardId": "finmb_177932577", "gmtOffSetMilliseconds": -18000000, "currentPrice": 4.87, "targetHighPrice": 16.0, "targetLowPrice": 8.0, "targetMeanPrice": 13.0, "targetMedianPrice": 13.0, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 126874000, "totalCashPerShare": 2.291, "ebitda": -70387000, "totalDebt": 2228000, "quickRatio": 13.208, "currentRatio": 13.393, "debtToEquity": 1.841, "returnOnAssets": -0.34325, "returnOnEquity": -0.57729, "freeCashflow": -31004376, "operatingCashflow": -57368000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-18"}]